CipherBio Weekly Digest: Week of Jan 27 – Feb 2, 2022

This week’s funding events bring $1.77B in deals, $421M in Series A, 40 new companies added to CipherBio. Furthermore, lot of notable announcements in product clinical phases.


Series A 

Series B 

Later Rounds 


New Companies on CipherBio

Sign Up For Your Weekly Digest ➜

Top Deals Across Rounds

Septerna raises $100M in Series A round led by Third Rock Ventures. Also in Series A Enable Injections gets $215M led by Magnetar Capital. In Series B Athelas raises $132M led by General Catalyst. Patient 21 raises $142M in Series C round led by Target Global. Alto Pharmacy raises $200M in Series E led by Softbank Vision Fund. Maravai Life Sciences acquires MyChem for $240M. Akili Interactive Labs merger with a SPAC will net it up to $412M.

See Investors Insights ➜
Company Round Amount
Septerna Series A $100M
Enable Injections Series A $215M
Athelas Series B $132M
Patient 21 Series C $142M
Alto Pharmacy Series E $200M
Maravai Life Sciences Acquisition $240M
Akili Interactive Labs SPAC $412M

This Week’s Lead Investors in Top Rounds

Lead investors this week are Third Rock Ventures, Magnetar Capital, General Catalyst, GV, Target Global, Softbank Vision Fund.

Third Rock Ventures   Profile Picture

See Investors Insights ➜

Products and Clinical Phases

Viracta Therapeutics announces phase 1B/2 trial of Nana-Val in patients with advanced Epstein-Barr virusTrevi Therapeutics completes enrollment in phase 2B/3 of Haduvio associated with chronic pruritus. Massachusetts-based   Viridian Announces announces phase 1 trial of VRDN-002 for the treatment of thyroid eye disease. Arcutis starts their phase 3 trial of topical roflumilast foam in people with seborrheic dermatitis. Reviva Pharmaceuticals begins a phase 3 study of their product Brilaroxazine for the treatment of schizophrenia.

See All Clinical Insights ➜
Company Product and Clinical Phase Indications
Viracta Therapeutics Nana-Val,  Phase 1B/2 Epstein-Barr Virus, EBV Associated Lymphoma, Solid Tumors, Cancers and Other Neoplasms (NOS)
Viridian Announces VRDN-002, Phase 1 Thyroid Eye Disease, Thyroid Disease, Eye Diseases
Aldeyra Reproxalap, Phase 2 Dry Eye Diseases, Dry Eye
Trevi Therapeutics Haduvio, Phase 2B/3 Pruritus, Peripheral Nervous System, Liver Disease
Arcutis Biotherapeutics Roflumilast, Phase 3 Skin Disease, Seborrheic Dermatitis
Reviva Brilaroxazine, Phase 3 Schizophrenia, Neurological Disorders, Psychiatric Disorders
Tracon Pharmaceuticals TRC102, Phase 2 Lung Cancer, Mesothelioma
Aardvark Therapeutics ARD 101, Phase 2 Metabolic Disorders, Inflammatory Disorders, Prader-Willi Syndrome

Starfield, food & science technology, raised $100M in Series B round led by Primavera Capital Group, Lightspeed China Partners and Joy Capital. FlipDish raised $100M in Series C led by Tencent. In AgTech MycoWorks raised $125M in Series C to build a new alt-leather factory. WayCool raised $117M in Series D led by LightRock, LightBox, FMO and others.

40 Life Science Companies Added

This week we added 40 new life science companies.

15 of 40 Companies
See Companies Insights ➜
Measure Labs Resilience Nude
Volta Labs Susterre Technologies Yamo Pharmaceuticals
Kula Bio Censys Iasis Molecular Science
Alpha10X Zetta Genomics Nuclera
Cropsy Koning ApolloMed

To get all the latest life science deals and VC funding data delivered straight to your inbox weekly become a CipherBio PRO member.

Get CipherBio PRO Account

Request Your PRO Demo

You May Also Like

Most Active Corporate VCs in the Life Science Industry

Co-authored by Matt Gibbs CipherBio@svb and Steve Agular SVB Managing Director, VC…
MicroBiome Insights

64 Microbiome Biotechs Raise $1.6 Billion in Investments

In the last decade, a relatively uncharted field exploded in the life…
CipherBio 2020 Biotech Industry Report

2020 Biotech Funding Overview

It has been an unprecedented year so far for Biotech industry and…
Q2 2020 Life Science Accelerators Insights

Q2 2020 Life Science Accelerators Insights

Co-authored by Matt Gibbs @cipherbio_gibbs, Ben Johnson SVB National Head of Early…